Figure 6From: Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experienceDistant PFS. 0: RIT as primary therapy; mean 30.2 months, 95% CI 24.7-35.7 months; 1: RIT for disease relapse; mean 12.5 months; 95% CI 8.9 - 16.2 months. 2: RIT as re-RT; mean 23.9 months; 95% CI 18.2 - 29.7 months. no statistically significant difference between the groupsBack to article page